,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2013', 'fs': 'Jul 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TrVrUAK'}, 'Id': 'a0P2P000005TrVrUAK', 'Event_Date__c': '2013-07-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2013', 'Status_History__c': 'a132P000000AqQLQA0'}, 'change': None}]",Jul 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2013', 'fs': 'Sep 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TrVsUAK'}, 'Id': 'a0P2P000005TrVsUAK', 'Event_Date__c': '2013-09-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2013', 'Status_History__c': 'a132P000000AqSpQAK'}, 'change': None}, {'Summary': {'s': 'Recommended with Special Authority critera. Also considered it appropriate to fund without restriction if cost-neutral to dabigatran.', 'fs': 'Recommended with Special Authority critera. Also considered it appropriate to fund without restriction if cost-neutral to dabigatran.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2013-09.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2013-09.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2013', 'fs': 'Sep 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.', 'fs': 'Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TrVtUAK'}, 'Id': 'a0P2P000005TrVtUAK', 'Event_Date__c': '2013-09-20', 'Event_Description__c': 'Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2013-09.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': 'Recommended with Special Authority critera. Also considered it appropriate to fund without restriction if cost-neutral to dabigatran.', 'Formatted_Date__c': 'Sep 2013', 'Status_History__c': 'a132P000000AqTQQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2013-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2013-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Haematology Subcommittee at meeting Friday 22 November 2013.', 'fs': 'Clinical advice received from Haematology Subcommittee at meeting Friday 22 November 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCrUAK'}, 'Id': 'a0P2P000005TsCrUAK', 'Event_Date__c': '2013-11-22', 'Event_Description__c': 'Clinical advice received from Haematology Subcommittee at meeting Friday 22 November 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2013-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqXlQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 27 February 2014.', 'fs': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 27 February 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCsUAK'}, 'Id': 'a0P2P000005TsCsUAK', 'Event_Date__c': '2014-02-27', 'Event_Description__c': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 27 February 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000AqcRQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCtUAK'}, 'Id': 'a0P2P000005TsCtUAK', 'Event_Date__c': '2014-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqepQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCuUAK'}, 'Id': 'a0P2P000005TsCuUAK', 'Event_Date__c': '2014-05-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqgXQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2014', 'fs': 'Nov 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCxUAK'}, 'Id': 'a0P2P000005TsCxUAK', 'Event_Date__c': '2014-11-06', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Nov 2014', 'Status_History__c': 'a132P000000AqpIQAS'}, 'change': None}, {'Summary': {'s': 'Discussed NOACs in general. Recommended seeking to fund two different anticoagulants with two different modes of action.', 'fs': 'Discussed NOACs in general. Recommended seeking to fund two different anticoagulants with two different modes of action.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 17 February 2016.', 'fs': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 17 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD0UAK'}, 'Id': 'a0P2P000005TsD0UAK', 'Event_Date__c': '2016-02-17', 'Event_Description__c': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 17 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'Discussed NOACs in general. Recommended seeking to fund two different anticoagulants with two different modes of action.', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar5dQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2016-4.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2016-4.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2016', 'fs': 'Mar 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 16 March 2016.', 'fs': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 16 March 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD1UAK'}, 'Id': 'a0P2P000005TsD1UAK', 'Event_Date__c': '2016-03-16', 'Event_Description__c': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 16 March 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2016-4.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Mar 2016', 'Status_History__c': 'a132P000000Ar6aQAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended funding another NOAC (of which apixaban is one) for patients unable to take dabigatran. This was recommended with a high priority.', 'fs': 'The Subcommittee recommended funding another NOAC (of which apixaban is one) for patients unable to take dabigatran. This was recommended with a high priority.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2017', 'fs': 'Sep 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 27 September 2017.', 'fs': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 27 September 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD2UAK'}, 'Id': 'a0P2P000005TsD2UAK', 'Event_Date__c': '2017-09-27', 'Event_Description__c': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 27 September 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended funding another NOAC (of which apixaban is one) for patients unable to take dabigatran. This was recommended with a high priority.', 'Formatted_Date__c': 'Sep 2017', 'Status_History__c': 'a132P000000ArLSQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 4 October 2017.', 'fs': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 4 October 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD3UAK'}, 'Id': 'a0P2P000005TsD3UAK', 'Event_Date__c': '2017-10-04', 'Event_Description__c': 'Clinical advice received from Haematology Subcommittee at meeting Wednesday 4 October 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Haematology Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2017', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ArLhQAK'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the Cardiovascular Subcommittee&#39;s recommendation.', 'fs': 'PTAC accepted the Cardiovascular Subcommittee&#39;s recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD4UAK'}, 'Id': 'a0P2P000005TsD4UAK', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Summary__c': 'PTAC accepted the Cardiovascular Subcommittee&#39;s recommendation.', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPwQAK'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the newer, medium priority, recommendation from the Haematology Subcommitee.', 'fs': 'PTAC accepted the newer, medium priority, recommendation from the Haematology Subcommitee.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2018', 'fs': 'May 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD6UAK'}, 'Id': 'a0P2P000005TsD6UAK', 'Event_Date__c': '2018-05-03', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Summary__c': 'PTAC accepted the newer, medium priority, recommendation from the Haematology Subcommitee.', 'Formatted_Date__c': 'May 2018', 'Status_History__c': 'a132P000000ArSKQA0'}, 'change': None}]",Sep 2013,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2013', 'fs': 'Sep 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TrVuUAK'}, 'Id': 'a0P2P000005TrVuUAK', 'Event_Date__c': '2013-09-20', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2013', 'Status_History__c': 'a132P000000AqTTQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCvUAK'}, 'Id': 'a0P2P000005TsCvUAK', 'Event_Date__c': '2014-05-08', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqgZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2014', 'fs': 'Nov 2014', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCyUAK'}, 'Id': 'a0P2P000005TsCyUAK', 'Event_Date__c': '2014-11-07', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2014', 'Status_History__c': 'a132P000000AqpiQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2018', 'fs': 'May 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD5UAK'}, 'Id': 'a0P2P000005TsD5UAK', 'Event_Date__c': '2018-05-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2018', 'Status_History__c': 'a132P000000ArRyQAK'}, 'change': None}]",Sep 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2014', 'fs': 'Aug 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCwUAK'}, 'Id': 'a0P2P000005TsCwUAK', 'Event_Date__c': '2014-08-29', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Aug 2014', 'Status_History__c': 'a132P000000AqmDQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2014', 'fs': 'Dec 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsCzUAK'}, 'Id': 'a0P2P000005TsCzUAK', 'Event_Date__c': '2014-12-03', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2014', 'Status_History__c': 'a132P000000Aqr0QAC'}, 'change': None}, {'Summary': {'s': 'Due to funding of rivaroxaban, Apixaban was moved from the OFI to the cost-neutral list. June2018', 'fs': 'Due to funding of rivaroxaban, Apixaban was moved from the OFI to the cost-neutral list. June2018', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000005TsD7UAK'}, 'Id': 'a0P2P000005TsD7UAK', 'Event_Date__c': '2018-06-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Summary__c': 'Due to funding of rivaroxaban, Apixaban was moved from the OFI to the cost-neutral list. June2018', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTlQAK'}, 'change': None}]",Aug 2014,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
